Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De novo design of a tumor-penetrating peptide.
Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E. Alberici L, et al. Among authors: bordignon c. Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14. Cancer Res. 2013. PMID: 23151901 Free PMC article.
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.
Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A. Curnis F, et al. Among authors: bordignon c. Cancer Res. 2008 Sep 1;68(17):7073-82. doi: 10.1158/0008-5472.CAN-08-1272. Cancer Res. 2008. PMID: 18757422
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.
Di Matteo P, Mangia P, Tiziano E, Valentinis B, Porcellini S, Doglioni C, Sanvito F, Bordignon C, Rizzardi GP, Traversari C. Di Matteo P, et al. Among authors: bordignon c. Clin Exp Metastasis. 2015 Mar;32(3):289-300. doi: 10.1007/s10585-015-9704-7. Epub 2015 Feb 4. Clin Exp Metastasis. 2015. PMID: 25648442
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: bordignon c. Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12. Eur J Cancer. 2010. PMID: 20708923 Clinical Trial.
Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.
Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C. Zucchelli E, et al. Among authors: bordignon c. Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17. Mol Ther Methods Clin Dev. 2017. PMID: 28344996 Free PMC article.
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Mammoliti S, et al. Among authors: bordignon c. Ann Oncol. 2011 Apr;22(4):973-978. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20. Ann Oncol. 2011. PMID: 20855468 Free PMC article. Clinical Trial.
204 results